News articles about Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals International earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 45.241274453825 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Buy Amazon, short Valeant among the top picks out of last year's Delivering Alpha (finance.yahoo.com)
- Today’s Research Reports on Trending Tickers: Endo International and Valeant Pharmaceuticals (finance.yahoo.com)
- Valeant Pharmaceuticals International, Inc. (VRX) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- $2.17 Billion in Sales Expected for Valeant Pharmaceuticals International, Inc. (VRX) This Quarter (americanbankingnews.com)
- $20 Should Be Your Cutoff Point (finance.yahoo.com)
VRX has been the topic of a number of recent research reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. BidaskClub downgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “sell” rating in a research note on Friday, June 16th. Vetr downgraded shares of Valeant Pharmaceuticals International from a “strong-buy” rating to a “buy” rating and set a $14.82 target price on the stock. in a research note on Monday, May 22nd. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 target price on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Finally, Deutsche Bank AG set a $18.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a research note on Friday, May 19th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and an average target price of $17.62.
Valeant Pharmaceuticals International (VRX) opened at 13.99 on Friday. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $27.84. The company’s market capitalization is $4.88 billion. The firm’s 50-day moving average is $14.48 and its 200 day moving average is $13.21.
Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. The company had revenue of $2.23 billion for the quarter, compared to analyst estimates of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The business’s revenue for the quarter was down 7.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.88) earnings per share. On average, equities analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current fiscal year.
In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De purchased 10,000 shares of the business’s stock in a transaction on Monday, August 21st. The shares were bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.87% of the stock is owned by corporate insiders.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.